الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 202 |  |  |
| | | from | 202 | | |
Abstract
The use of thiazolidinediones (TZDs) for treating patients with type 2 diabetes mellitus (T2DM) has been expansively increasing. Although troglitazone was withdrawn from the market, rosiglitazone and pioglitazone are currently available in several countries worldwide.
The effects of TZDs are explained by their peroxisome proliferator activator receptor- γ (PPAR γ) activating characteristics.
Widespread of PPAR γ receptors in many tissues leading to the pleiotropic effects of thiazolidinediones .
They have been shown to lower the levels of atherogenic dyslipidemia, lower visceral obesity, lessen the levels of the proinflammatory and prothrombotic cytokines and adipokines as well as increase the levels of the antiatherogenic adinopectin. They decrease levels of PAI-1 and fibrinogen thereby lowering the procoagulant state and have a salutary effect on endothelial function
Also anti inflammatory and antineoplastic effects of PPAR γ receptors are leading to many studies of TZDs on many diseases.